Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses

References

• Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777–783.
   PubMed Web of Science ®Google Scholar
• Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008;49:27–35.
   PubMed Web of Science ®Google Scholar
• Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000;465:143–151.
   PubMedGoogle Scholar
• Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205–212.
   PubMed Web of Science ®Google Scholar
• Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 2008;13:756–770.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482:193–199.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007;67:333–350.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Vaccarezza M, Gonelli A, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004;10:3673–3681.
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847–853.
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003;22:2034–2044.
   PubMed Web of Science ®Google Scholar
• Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734–741.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo [see comments]. Nat Med 1999;5:157–163.
   PubMed Web of Science ®Google Scholar
• Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006;11:1175–1193.
   PubMed Web of Science ®Google Scholar
• Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335–346.
   PubMed Web of Science ®Google Scholar
• Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735–1743.
   PubMed Web of Science ®Google Scholar
• Shetty S, Gladden JB, Henson ES, et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 2002;7:413–420.
   PubMed Web of Science ®Google Scholar
• Jacobson K, Mouritsen OG, Anderson RG. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 2007;9:7–14.
   PubMed Web of Science ®Google Scholar
• Vanoosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005;11:542–552.
   PubMed Web of Science ®Google Scholar
• Song JH, Tse MC, Bellail A, et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007;67:6946–6955.
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006;26:7046–7055.
   PubMed Web of Science ®Google Scholar
• Delmas D, Rebe C, Micheau O, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004;23:8979–8986.
   PubMed Web of Science ®Google Scholar
• Min Y, Shi J, Zhang Y, Liu S, Liu Y, Zheng D. Death receptor 5-recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAIL-induced cell death. IUBMB Life 2009;61:261–267.
   PubMed Web of Science ®Google Scholar
• Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2002:193–213.
   PubMedGoogle Scholar
• MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809–6818.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356–8369.
   PubMed Web of Science ®Google Scholar
• Olsson A, Diaz T, Aguilar-Santelises M, et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001;15:1868–1877.
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Inoue S, Kohlhaas SL, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005;12:773–782.
   PubMed Web of Science ®Google Scholar
• Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem 2005;280:9498–9508.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Wakelee HA, von Mehren M, et al. A phase 1b study to access the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2 in combination with gemcitabine, pemetrexed, doxorubicin, or FOLFIRI. J Clin Oncol 2007;25(18 Suppl.): Abstract 14006.
   PubMed Web of Science ®Google Scholar
• Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009;8:292–302.
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187–6194.
   PubMed Web of Science ®Google Scholar
• Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 2008;181:4019–4026.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839–2846.
   PubMed Web of Science ®Google Scholar
• Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004;11(Suppl. 2):S193–S206.
   PubMed Web of Science ®Google Scholar
• Hetschko H, Voss V, Seifert V, Prehn JH, Kogel D. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J 2008;275:1925–1936.
   PubMed Web of Science ®Google Scholar
• Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res 2008;68:266–275.
   PubMed Web of Science ®Google Scholar
• Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007;313:2378–2388.
   PubMed Web of Science ®Google Scholar
• Rossin A, Derouet M, Abdel-Sater F, Hueber AO. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 2009;419:185–192, 2 p following 192.
   PubMed Web of Science ®Google Scholar
• Shetty S, Graham BA, Brown JG, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005;25:5404–5416.
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Graham BA, Hu X, et al. Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. J Biol Chem 2008;283:16818–16829.
   PubMed Web of Science ®Google Scholar
• Moretto P, Hotte SJ. Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin Investig Drugs 2009;18:311–325.
   PubMed Web of Science ®Google Scholar
• Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61:82–90.
   PubMed Web of Science ®Google Scholar